NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Tuesday that its third-quarter revenues increased 21 percent year over year, with sales of the firm's BART test jumping nearly 400 percent.

The Salt Lake City-based molecular diagnostics company brought in total revenues of $156.5 million for the three months ended March 31, compared to $129.8 million for the third quarter of 2012. It beat the consensus Wall Street estimate for revenues of $148.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.